Preferred Label : Cobicistat;
MeSH definition : A carbamate and thiazole derivative that functions as a CYTOCHROME P450 CYP3A INHIBITOR
to enhance the concentration of ANTI-HIV AGENTS, with which it is used in combination,
for the treatment of HIV INFECTIONS.;
MeSH hyponym : Tybost; GS 9350; 9350, GS; GS9350; GS-9350;
Wikipedia link : https://en.wikipedia.org/wiki/Cobicistat;
Is substance : O;
UNII : LW2E03M5PG;
Origin ID : D000069547;
UMLS CUI : C3177235;
ATC code(s)
Allowable qualifiers
CISMeF manual mappings
Currated CISMeF NLP mapping
Exact mapping(s) to DCI
Pharmacological action(s)
Record concept(s)
Related MeSH Supplementary Concept(s)
Semantic type(s)
UMLS correspondences (same concept)
A carbamate and thiazole derivative that functions as a CYTOCHROME P450 CYP3A INHIBITOR
to enhance the concentration of ANTI-HIV AGENTS, with which it is used in combination,
for the treatment of HIV INFECTIONS.
https://ansm.sante.fr/informations-de-securite/genvoya-r-stribild-r-risque-accru-dechec-virologique-et-secondairement-de-transmission-de-linfection-vih-de-la-mere-a-lenfant
2019
false
false
false
France
French
infectious disease transmission, vertical
treatment failure
hiv infections
pregnancy trimester, second
pregnancy trimester, third
hiv infections
pharmacovigilance note
anti-hiv agents
elvitegravir
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
guidelines for drug use
risk
emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
pregnancy
infant, newborn
elvitegravir
Emtricitabine
Tenofovir
Cobicistat
drug combinations
quinolones
quinolones
---
https://www.has-sante.fr/portail/jcms/c_2886171/fr/symtuza-darunavir-/cobicistat-/emtricitabine-/tenofovir-alafenamide-association-d-antiviraux
2018
false
false
false
France
French
drug combinations
treatment outcome
anti-hiv agents
hiv infections
adult
adolescent
administration, oral
Cytochrome P-450 CYP3A Inhibitors
hiv protease inhibitors
reverse transcriptase inhibitors
antivirals for systemic use
evaluation of the transparency committee
insurance, health, reimbursement
guidelines for drug use
Tenofovir
Darunavir
Cobicistat
tenofovir alafenamide
Emtricitabine
tenofovir alafenamide
adenine
Darunavir Ethanolate/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate
---
https://www.has-sante.fr/portail/jcms/c_2863577/fr/symtuza
2018
false
false
false
France
French
drug combinations
treatment outcome
anti-hiv agents
hiv infections
adult
adolescent
administration, oral
Cytochrome P-450 CYP3A Inhibitors
hiv protease inhibitors
reverse transcriptase inhibitors
antivirals for systemic use
evaluation of the transparency committee
insurance, health, reimbursement
Tenofovir
Darunavir
Cobicistat
tenofovir alafenamide
Emtricitabine
tenofovir alafenamide
adenine
Darunavir Ethanolate/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate
---
https://www.ema.europa.eu/medicines/human/EPAR/Symtuza
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
Darunavir
Cobicistat
drug approval
europe
treatment outcome
Emtricitabine
tenofovir alafenamide
anti-hiv agents
anti-hiv agents
hiv infections
product surveillance, postmarketing
adult
adolescent
administration, oral
tablets
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 CYP3A Inhibitors
hiv protease inhibitors
hiv protease inhibitors
reverse transcriptase inhibitors
reverse transcriptase inhibitors
tenofovir alafenamide
antivirals for systemic use
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
Tenofovir
Darunavir
Cobicistat
tenofovir alafenamide
Emtricitabine
tenofovir alafenamide
adenine
Darunavir Ethanolate/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate
---
http://www.has-sante.fr/portail/jcms/c_2621468/fr/genvoya
http://www.has-sante.fr/portail/jcms/c_2621468/fr/genvoya-emtricitabine-cobicistat-elvitegravir-et-tenofovir-alafenamide-association-d-antiviraux
2016
false
false
false
France
French
treatment outcome
drug combinations
tenofovir alafenamide
elvitegravir
hiv infections
anti-hiv agents
adult
adolescent
human immunodeficiency virus i infection
administration, oral
HIV integrase inhibitors
reverse transcriptase inhibitors
emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
Cobicistat
Emtricitabine
evaluation of the transparency committee
guidelines for drug use
tenofovir alafenamide
elvitegravir
adenine
adenine
quinolones
---
http://www.has-sante.fr/portail/jcms/c_2607076/fr/rezolsta
http://www.has-sante.fr/portail/jcms/c_2607076/fr/rezolsta-darunavir/cobicistat-antiretroviral
2016
false
France
French
evaluation of the transparency committee
hiv infections
human immunodeficiency virus i infection
Genotype drug resistance test positive
drug therapy, combination
Cobicistat
Darunavir
darunavir and cobicistat
guidelines for drug use
drug interactions
withholding treatment
treatment outcome
adult
HIV-1
hiv infections
drug combinations
administration, oral
drug synergism
hiv protease inhibitors
cytochrome p-450 cyp3a
cobicistat mixture with darunavir
---
https://www.ema.europa.eu/medicines/human/EPAR/Genvoya
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
drug approval
europe
tenofovir alafenamide
tenofovir alafenamide
elvitegravir
elvitegravir
hiv infections
drug interactions
pregnancy
breast feeding
product surveillance, postmarketing
drug evaluation, preclinical
anti-hiv agents
anti-hiv agents
adult
adolescent
human immunodeficiency virus i infection
administration, oral
Substance with integrase strand transfer inhibitor mechanism of action (substance)
HIV integrase inhibitors
HIV integrase inhibitors
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 CYP3A Inhibitors
reverse transcriptase inhibitors
reverse transcriptase inhibitors
emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
Cobicistat
Cobicistat
Emtricitabine
Emtricitabine
tenofovir alafenamide
tenofovir alafenamide
elvitegravir
elvitegravir
adenine
adenine
adenine
quinolones
quinolones
---
https://www.ema.europa.eu/medicines/human/EPAR/Evotaz
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
hiv protease inhibitors
hiv protease inhibitors
hiv infections
anti-hiv agents
anti-hiv agents
adult
HIV-1
human immunodeficiency virus i infection
administration, oral
drug approval
europe
drug monitoring
product surveillance, postmarketing
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 CYP3A Inhibitors
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
atazanavir and cobicistat
Atazanavir Sulfate
Atazanavir Sulfate
Cobicistat
Cobicistat
Atazanavir/Cobicistat
---
http://www.has-sante.fr/portail/jcms/c_1742475/fr/tybost
2014
false
France
French
cobicistat
administration, oral
insurance, health, reimbursement
treatment outcome
drug synergism
adult
hiv infections
drug therapy, combination
HIV-1
anti-retroviral agents
evaluation of the transparency committee
guidelines for drug use
Cobicistat
Cobicistat
Darunavir
Atazanavir Sulfate
---
https://www.ema.europa.eu/medicines/human/EPAR/Rezolsta
2014
false
United Kingdom
French
English
hiv protease inhibitors
Darunavir
Darunavir
Cobicistat
Cobicistat
darunavir and cobicistat
drug approval
europe
treatment outcome
adult
HIV-1
hiv infections
drug combinations
administration, oral
drug synergism
hiv protease inhibitors
cytochrome p-450 cyp3a
continuity of patient care
drug monitoring
drug interactions
pregnancy
breast feeding
controlled clinical trials as topic
drug evaluation, preclinical
summary of product characteristics
package leaflet
drug evaluation
syndication feed
cobicistat mixture with darunavir
cobicistat mixture with darunavir
---
https://www.ema.europa.eu/medicines/human/EPAR/Tybost
2013
false
United Kingdom
French
English
Cobicistat
Cobicistat
Atazanavir Sulfate
Darunavir
cobicistat
drug approval
europe
treatment outcome
adult
HIV-1
hiv infections
drug therapy, combination
administration, oral
drug synergism
hiv protease inhibitors
cytochrome p-450 cyp3a
continuity of patient care
drug monitoring
drug interactions
pregnancy
breast feeding
controlled clinical trials as topic
drug evaluation, preclinical
summary of product characteristics
package leaflet
drug evaluation
syndication feed
---